Abstract
Severe brain trauma remains poorly understood, because of its pathophysiological complexity, and this has so far thwarted our attempts to improve outcome by means of drug therapy, although better understanding of the role of ischemic events has led to improved mortality rates, in some centers. With regard to excitatory amino acid antagonists, new mechanistic insights from both animal models, and human monitoring has enabled better trial design, which may allow the tremendous laboratory neuroprotective potency of this group of compounds to be translated to clinical benefit.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
